vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 22,900 shares, a growth of 42.2% from the March 31st total of 16,100 shares. Based on an average trading volume of 22,000 shares, the days-to-cover ratio is presently 1.0 days. Currently, 1.6% of the company's stock are sold short.
Analysts Set New Price Targets
VTVT has been the topic of a number of recent research reports. HC Wainwright initiated coverage on vTv Therapeutics in a research note on Wednesday, April 9th. They issued a "buy" rating and a $36.00 target price on the stock. StockNews.com started coverage on vTv Therapeutics in a research note on Wednesday, April 16th. They issued a "sell" rating for the company.
View Our Latest Report on VTVT
Institutional Investors Weigh In On vTv Therapeutics
An institutional investor recently raised its position in vTv Therapeutics stock. Geode Capital Management LLC boosted its holdings in vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,634 shares of the biotechnology company's stock after buying an additional 1,327 shares during the period. Geode Capital Management LLC owned approximately 0.36% of vTv Therapeutics worth $158,000 as of its most recent SEC filing. 17.51% of the stock is owned by hedge funds and other institutional investors.
vTv Therapeutics Price Performance
Shares of VTVT stock traded up $1.95 on Friday, hitting $22.46. The company's stock had a trading volume of 4,279 shares, compared to its average volume of 23,282. The stock has a market capitalization of $71.65 million, a price-to-earnings ratio of -4.96 and a beta of 0.77. vTv Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $29.01. The firm's fifty day moving average price is $18.24 and its 200-day moving average price is $16.44.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.32. The company had revenue of $0.02 million during the quarter.
About vTv Therapeutics
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Read More
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
